Using existing treatments to lower the risk of Parkinson's disease.
Repurposing Existing Therapies for Parkinson's Disease Risk and Phenoconversion
['FUNDING_R21'] · JOHNS HOPKINS UNIVERSITY · NIH-11036331
This study is looking at how some existing treatments for inflammation and autoimmune diseases might help lower the chances of developing Parkinson's disease, especially for people who have early symptoms but haven't been diagnosed yet. If you have an autoimmune condition, your participation could help us find ways to prevent or delay Parkinson's disease.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11036331 on ClinicalTrials.gov |
What this research studies
This research investigates how existing therapies, particularly those targeting inflammation and autoimmune conditions, can be repurposed to reduce the risk of developing Parkinson's disease (PD). It focuses on understanding the prodromal phase of PD, where individuals may experience early, non-specific symptoms before a formal diagnosis. By examining the relationship between chronic inflammation and PD risk, the study aims to identify potential preventive strategies that could delay or prevent the onset of the disease. Patients with autoimmune disorders may be particularly relevant to this research, as certain treatments for these conditions may influence PD risk.
Who could benefit from this research
Good fit: Ideal candidates for participation include individuals with autoimmune disorders or those experiencing early symptoms of Parkinson's disease.
Not a fit: Patients who are already diagnosed with advanced Parkinson's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new preventive strategies for Parkinson's disease, potentially reducing the incidence and severity of the condition.
How similar studies have performed: Previous research has shown promise in repurposing therapies for other neurological conditions, suggesting potential for success in this novel approach.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FITZGERALD, KATHRYN C. — JOHNS HOPKINS UNIVERSITY
- Study coordinator: FITZGERALD, KATHRYN C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer's disease risk, Autoimmune Diseases, autoimmune disorder, autoimmunity disease